NTRK、ROS1、またはALK遺伝子融合変異を伴う局所進行性/転移性固形腫瘍患者におけるSIM1803-1Aの安全性、有効性、および薬物動態特性を評価するための非盲検多施設第I相臨床試験。
This research study is done to test the safety, effectiveness and pharmacokinetic characteristics of SIM1803-1A in patients with locally advanced/metastatic solid tumors with NTRK, ROS1 or ALK gene fusion mutations. The cancer must have a change in a particular gene (NTRK1, NTRK2, NTRK3, ROS1 or ALK). SIM1803-1A is a drug that blocks the actions of these NTRK/ ROS1 /ALK genes in cancer cells and can therefore be used to treat cancer.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
-
Shanghai、中国
- Shanghai Chest Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adult patients with a locally advanced or metastatic solid tumor that has progressed or was nonresponsive to available therapies, are unfit for standard chemotherapy or for which no standard or available curative therapy exists;Proof of a malignancy harboring a NTRK、ROS1 or ALK fusion;Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 and a life expectancy of at least 3 month;Adequate hematologic, hepatic, and renal function;Signed informed consent form;
Exclusion Criteria:
- Any contraindications as listed in the local approved product information;Patients with unstable primary central-nervous-system tumors or metastasis, exceptions possible;Pregnancy or lactation;Clinically significant active cardiovascular disease or history of myocardial infarction;Participation in an investigational program with interventions outside of routine clinical practice;Prior treatment with other kinase inhibitor with tropomyosin receptor kinase inhibition;Active uncontrolled systemic bacterial, viral, or fungal infection;Current treatment with a strong CYP3A4 inhibitor or inducer;
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:成人患者_用量 1
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
実験的:成人患者_用量 2
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
実験的:成人患者_用量 3
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
実験的:成人患者_用量4
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
実験的:成人患者_用量 5
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
実験的:成人患者_用量6
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
実験的:成人患者_用量 7
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
実験的:成人患者_8回分
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants with adverse events
時間枠:5 years
|
Number of participants with adverse events |
5 years
|
|
Severity of adverse events
時間枠:5 years
|
Severity of adverse events |
5 years
|
|
Maximum tolerated dose
時間枠:5 years
|
Maximum tolerated dose |
5 years
|
|
Recommended dose for dose expansion
時間枠:5 years
|
Recommended dose for dose expansion |
5 years
|
|
Maximum concentration of SIM1803-1A in plasma (Cmax)
時間枠:Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
Maximum concentration of SIM1803-1A in plasma (Cmax) |
Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted)
時間枠:Up to 1 day
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted) |
Up to 1 day
|
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to infinity in fasted state (AUC_fasted)
時間枠:Up to 3 days
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to infinity in fasted state (AUC_fasted) |
Up to 3 days
|
|
Number of participants with treatment-emergent adverse events (TEAEs)
時間枠:Up to 24 weeks
|
Number of participants with treatment-emergent adverse events (TEAEs) |
Up to 24 weeks
|
|
Time to maximum concentration of SIM1803-1A in plasma (Tmax)
時間枠:Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
Time to maximum concentration of SIM1803-1A in plasma (Tmax) |
Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Response Rate (ORR)
時間枠:Up to 60 months
|
Overall Response Rate (ORR) |
Up to 60 months
|
|
Duration of Response (DOR)
時間枠:Up to 60 months
|
Duration of Response (DOR) |
Up to 60 months
|
|
progression-free survival(PFS)
時間枠:Up to 60 months
|
progression-free survival(PFS) |
Up to 60 months
|
協力者と研究者
捜査官
- 主任研究者:shun lu, Ph.D、Shanghai Chest Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- SIM1803-1A-NTRK-0101
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。